ABSTRACT
With its high prevalence and the eminent number of undetected or poorly controlled patients, the management of arterial hypertension is still a challenging task. Uncontrolled blood pressure is the major adjustable risk factor for cardiovascular end organ damage for coronary heart disease, heart failure, stroke, and renal disease. Patients with resistant hypertension often need a multidisciplinary approach in order to control their blood pressure sustainably. In cooperation with hypertension specialists, the underlying cause for therapy resistance should be evaluated. Pseudohypertension, white coat hypertension, and non-adherence need to be addressed. The medication can often be optimized and simplified. Reducing the number of pills per day can enhance the drug-adherence remarkably. The multidisciplinary evaluation of secondary causes of hypertension includes an endocrinological work-up, ruling out relevant sleeping disorders, and renal diagnostics. If there are no causative treatments possible and pharmacological and non-pharmacological measurements are not sufficient to control the blood pressure, one has to consider multidisciplinary approaches bringing nurses, pharmacists, dieticians, physiotherapists, social workers, psychologists, and community health workers onboard. Utilizing various strategies might improve medication management, patient follow-up, adherence, and self-management. Interventional therapy such as renal renervation, baroreflex activation therapy, or carotid body modulation is the final option that can be discussed with interventional active colleagues. However, large randomized controlled trials proving a benefit of these interventional therapies are still missing. The use of these still experimental approaches should be restricted to randomized controlled trials accordingly.
Subject(s)
Hypertension/therapy , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Blood Pressure Determination , Drug Resistance , Humans , Risk FactorsABSTRACT
INTRODUCTION: An excess of angiotensin II (Ang II) causes hypertension and vascular injury. Activation of mitogen-activated protein kinase p38 (p38-MAPK) plays a substantial role in Ang II-dependent organ damage. Recently, we showed that p38-MAPK activation regulates the pressor response to Ang II. This study evaluates the effect of chronic p38-MAPK inhibition in Ang II-dependent hypertension. MATERIALS AND METHODS: C57Bl/6J mice were infused with Ang II for 14 days and either treated with the p38-MAPK inhibitor BIRB796 (50 mg/kg/day) or the vehicle as the control. We assessed vascular function in the aorta and isolated perfused kidneys. RESULTS: Chronic p38-MAPK inhibition did not alter blood pressure at the baseline, but attenuated Ang II-induced hypertension significantly (baseline: 122 ± 2 versus 119 ± 4 mmHg; Ang II: 173 ± 3 versus 155 ± 3 mmHg; p < 0.001). In addition, BIRB796 treatment improved vascular remodeling by reducing the aortic media-to-lumen ratio and decreasing the expression of the membrane metalloproteinases (MMP) MMP-1 and MMP-9. Moreover, renal vascular dysfunction induced by chronic Ang II infusion was significantly ameliorated in the BIRP796-treated mice. Acute p38-MAPK inhibition also improved vascular function in the aorta and kidneys of Ang II-treated mice, highlighting the important role of p38-MAPK activation in the pathogenesis of vascular dysfunction. CONCLUSIONS: Our findings indicated there is an important role for p38-MAPK in regulating blood pressure and vascular injury, and highlighted its potential as a pharmaceutical target.
Subject(s)
Aorta/physiopathology , Hypertension/physiopathology , Protein Kinase Inhibitors/pharmacology , Vascular Remodeling/drug effects , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , Angiotensin II , Animals , Aorta/drug effects , Blood Pressure/drug effects , Hypertension/enzymology , Kidney/drug effects , Kidney/physiopathology , Mice, Inbred C57BL , Perfusion , S-Nitrosoglutathione/pharmacology , Systole/drug effectsABSTRACT
Iron deficiency often occurs in patients with chronic kidney disease and can be effectively treated with parenteral supplementation of iron. In these patients, prompt application of iron therapy can help to reduce the dependence of erythropoietin-stimulating agents and effectively treat anemia. Correct evaluation of iron metabolism in CKD patients can be difficult. Duration of and response to therapy should always be considered while planning parenteral supplementation of iron. The main safety aspects of parenteral iron preparations relate to their possible anaphylactic potential and the potential induction of oxidative stress due to the release of free iron. However, parenteral iron supplementation is usually safe and without major side effects. Regarding current data, none of the iron preparations is showing definitive superiority. Although uncommon, iron preparations containing dextran can lead to severe side effects, therefore these preparations appear to have an inferior safety profile. Due to limited data, a comparison of third-generation iron preparations with previous preparations is not possible. Recently, for the first time, the third generation iron preparation ferumoxytol has been directly compared to iron sucrose. From this data and others, it remains unclear whether third generation iron preparations show safety-relevant superiority.
Subject(s)
Anemia, Iron-Deficiency/drug therapy , Iron Compounds/administration & dosage , Iron Compounds/adverse effects , Kidney Failure, Chronic/complications , Administration, Oral , Anaphylaxis/chemically induced , Disaccharides/adverse effects , Disaccharides/therapeutic use , Ferric Compounds/adverse effects , Ferric Compounds/therapeutic use , Ferric Oxide, Saccharated , Ferrosoferric Oxide/adverse effects , Ferrosoferric Oxide/therapeutic use , Glucaric Acid/adverse effects , Glucaric Acid/therapeutic use , Humans , Infusions, Intravenous , Iron-Dextran Complex/adverse effects , Iron-Dextran Complex/therapeutic use , Kidney Failure, Chronic/therapy , Maltose/adverse effects , Maltose/analogs & derivatives , Maltose/therapeutic use , Oxidative Stress/drug effects , Oxidative Stress/physiology , Renal DialysisSubject(s)
Hypertension/therapy , Antihypertensive Agents/adverse effects , Antihypertensive Agents/therapeutic use , Humans , Hypertension/complications , Hypertension/etiology , Hypertension, Renovascular/etiology , Hypertension, Renovascular/therapy , Kidney/blood supply , Kidney/innervation , Renal Artery/surgery , Renin-Angiotensin System/drug effects , SympathectomyABSTRACT
Primary hyperaldosteronism (PHA) is characterized by an increased Aldosterone synthesis which is independent of the Renin-Angiotensin-Aldosterone-System (RAAS). The prevalence of PHA in patients who present in specialized hypertension centers is approx. 10 %. Besides patients with the classical symptoms known as "Conn-Trias" (hypertension, hypokalemia, metabolic alkalosis), the more frequent normokalemic patients with PHA also show a worse outcome compared to patients with essential hypertension. Identifying these patients is an important task in the evaluation of hypertension since targeted treatment options are available. Screening for PHA using the Aldosterone-Renin-Ratio (ARR) should be performed in patients with hypokalemic, severe or resistant hypertension. In addition, young patients with early onset of severe hypertension and/or positive family history should be screened. A positive screening result should be followed by a confirmatory test. The saline infusion test is the preferred clinical test for confirming a suspected PHA since it is accessible and time efficient. Other confirmatory tests are not used on a regular basis. After any confirmatory test, CT- or MRI-imaging and adrenal vein sampling (AVS) is used in order to differentiate between a unilateral adenoma, a bilateral hyperplasia or another cause of PHA. CT or MRI usually cannot discriminate smaller tumors form hyperplasia. Therefore AVS is used to detect lateralization of autonomous aldosterone production. Lateralization of aldosterone production indicates a unilateral adenoma. In these cases, laparoscopic adrenalectomy is the therapeutic option of choice with a hypertension cure rate of up to 60 %. If no lateralization is detectable, bilateral hyperplasia as the underlying cause of PHA is likely. Pharmacological inhibition of the mineralocorticoid receptor is the preferred treatment option in these cases. If Spironolactone is not well tolerated, Eplerenone and potassium-sparing diuretics should be prescribed. Often, however, in order to fully control hypertension, additional antihypertensive therapy is necessary.
Subject(s)
Hyperaldosteronism/diagnosis , Hypertension/etiology , Adrenal Cortex Neoplasms/blood , Adrenal Cortex Neoplasms/diagnosis , Adrenal Cortex Neoplasms/therapy , Adrenal Glands/pathology , Adrenal Hyperplasia, Congenital/blood , Adrenal Hyperplasia, Congenital/diagnosis , Adrenal Hyperplasia, Congenital/therapy , Adrenocortical Adenoma/blood , Adrenocortical Adenoma/diagnosis , Adrenocortical Adenoma/therapy , Aldosterone/blood , Antihypertensive Agents/therapeutic use , Diagnosis, Differential , Eplerenone , Hyperaldosteronism/blood , Hyperaldosteronism/drug therapy , Hyperaldosteronism/etiology , Hypertension/blood , Hypertension/drug therapy , Hypokalemia/blood , Hypokalemia/diagnosis , Hypokalemia/drug therapy , Magnetic Resonance Imaging , Mass Screening , Renin/blood , Spironolactone/analogs & derivatives , Spironolactone/therapeutic use , Tomography, X-Ray ComputedSubject(s)
Brain Edema/diagnosis , Kidney Transplantation , Posterior Leukoencephalopathy Syndrome/diagnosis , Postoperative Complications/diagnosis , Seizures/etiology , Adolescent , Brain/pathology , Brain Edema/etiology , Diagnosis, Differential , Dominance, Cerebral/physiology , Female , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Magnetic Resonance Imaging , Posterior Leukoencephalopathy Syndrome/etiology , Postoperative Complications/etiology , Recurrence , Remission, Spontaneous , Risk FactorsABSTRACT
This commentary summarizes the expert consensus and recommendations of the working group 'Herz und Niere' of the German Society of Cardiology (DGK), the German Society of Nephrology (DGfN) and the German Hypertension League (DHL) on renal denervation for antihypertensive treatment. Renal denervation is a new, interventional approach to selectively denervate renal afferent and efferent sympathetic fibers. Renal denervation has been demonstrated to reduce office systolic and diastolic blood pressure in patients with resistant hypertension, defined as systolic office blood pressure ≥ 160 mm Hg and ≥ 150 mm Hg in patients with diabetes type 2, which should currently be used as blood pressure thresholds for undergoing the procedure. Exclusion of secondary hypertension causes and optimized antihypertensive drug treatment is mandatory in every patient with resistant hypertension. In order to exclude pseudoresistance, 24-hour blood pressure measurements should be performed. Preserved renal function was an inclusion criterion in the Symplicity studies, therefore, renal denervation should be only considered in patients with a glomerular filtration rate > 45 ml/min. Adequate centre qualification in both, treatment of hypertension and interventional expertise are essential to ensure correct patient selection and procedural safety. Long-term follow-up after renal denervation and participation in the German Renal Denervation (GREAT) Registry are recommended to assess safety and efficacy after renal denervation over time.
Subject(s)
Catheter Ablation , Hypertension, Renal/surgery , Renal Artery/innervation , Sympathectomy/methods , Adolescent , Adult , Aged , Aged, 80 and over , Angiography , Blood Glucose/metabolism , Blood Pressure , Blood Pressure Monitoring, Ambulatory , Diagnosis, Differential , Follow-Up Studies , Heart Rate , Humans , Hypertension, Renal/diagnosis , Hypertension, Renal/drug therapy , Hypertension, Renal/etiology , Middle Aged , Randomized Controlled Trials as Topic , Registries , Young AdultABSTRACT
Recent data suggests that chronic renal failure and hyperparathyroidism are associated with sympathetic overactivity. Since peptide hormones are known to modulate norepinephrine (NE) release by activating prejunctional receptors, this study investigates whether parathyroid hormone fragment (1-34) (hPTH(1-34)) increases neuronal NE release in human heart and kidney. Using specific PTH-receptor agonists and antagonists, this study furthermore highlights functional differences between PTH1 and PTH2 receptors. Human atrial and renal tissues were incubated with [(3)H]-NE and superfused. Three electrical stimulations (5Hz, 1min) induced a stable [(3)H]-NE release which was taken as an index of endogenous NE release. RT-PCR with specific primers for PTH1- and PTH2-receptor was performed in heart and kidney. hPTH(1-34) (0.01-0.1µmol/L) and a stable analog of its second messenger cAMP (8-bromo-cAMP) increased [(3)H]-NE release in human atria. This facilitatory effect of PTH was also observed in human renal cortex. The PTH1-receptor antagonist (D-Trp(12), Tyr(34))-pTH-(7-34) (0.5µmol/L) abolished the effect of hPTH(1-34). This data was verified using isolated perfused mouse kidneys. Tuberoinfundibular peptide of 39 residues (TIP-39) (0.1nmol/L-0.1µmol/L) decreased [(3)H]-NE release in atria. PTH1- and PTH2-receptor expressions were demonstrated in human heart and kidney. Moreover, a splice variant of the PTH2-receptor was detected in human kidney. In conclusion, PTH is able to facilitate NE release in human atria and renal cortex by activation of PTH1-receptors. The highly increased PTH levels that can be observed in chronic renal failure might be one contributor for the elevated sympathetic nerve activity and the associated cardiovascular mortality in patients with end stage renal disease.
Subject(s)
Heart/metabolism , Kidney/metabolism , Neuropeptides/metabolism , Norepinephrine/metabolism , Parathyroid Hormone/metabolism , Peptide Fragments/metabolism , Receptor, Parathyroid Hormone, Type 1/metabolism , Receptor, Parathyroid Hormone, Type 2/metabolism , Aged , Aged, 80 and over , Animals , Cells, Cultured , Cocaine/administration & dosage , Cocaine/pharmacology , Corticosterone/administration & dosage , Corticosterone/pharmacology , Humans , Kidney Failure, Chronic/etiology , Mice , Middle Aged , Receptor, Parathyroid Hormone, Type 1/agonists , Receptor, Parathyroid Hormone, Type 1/antagonists & inhibitors , Receptor, Parathyroid Hormone, Type 1/genetics , Receptor, Parathyroid Hormone, Type 2/agonists , Receptor, Parathyroid Hormone, Type 2/antagonists & inhibitors , Receptor, Parathyroid Hormone, Type 2/genetics , Synaptic Transmission/physiologyABSTRACT
BACKGROUND AND PURPOSE: ApolipoproteinE-deficient [apoE (-/-)] mice, a model of human atherosclerosis, develop endothelial dysfunction caused by decreased levels of nitric oxide (NO). The endogenous peptide, angiotensin-(1-7) [Ang-(1-7)], acting through its specific GPCR, the Mas receptor, has endothelium-dependent vasodilator properties. Here we have investigated if chronic treatment with Ang-(1-7) improved endothelial dysfunction in apoE (-/-) mice. EXPERIMENTAL APPROACH: ApoE (-/-) mice fed on a lipid-rich Western diet were divided into three groups and treated via osmotic minipumps with either saline, Ang-(1-7) (82 µg·kg(-1) ·h(-1) ) or the same dose of Ang-(1-7) together with D-Ala-Ang-(1-7) (125 µg·kg(-1) ·h(-1) ) for 6 weeks. Renal vascular function was assessed in isolated perfused kidneys. KEY RESULTS: Ang-(1-7)-treated apoE (-/-) mice showed improved renal endothelium-dependent vasorelaxation induced by carbachol and increased renal basal cGMP production, compared with untreated apoE (-/-) mice. Tempol, a reactive oxygen species (ROS) scavenger, improved endothelium-dependent vasorelaxation in kidneys of saline-treated apoE (-/-) mice whereas no effect was observed in Ang-(1-7)-treated mice. Chronic treatment with D-Ala-Ang-(1-7), a specific Mas receptor antagonist, abolished the beneficial effects of Ang-(1-7) on endothelium-dependent vasorelaxation. Renal endothelium-independent vasorelaxation showed no differences between treated and untreated mice. ROS production and expression levels of the NAD(P)H oxidase subunits gp91phox and p47phox were reduced in isolated preglomerular arterioles of Ang-(1-7)-treated mice, compared with untreated mice, whereas eNOS expression was increased. CONCLUSION AND IMPLICATIONS: Chronic infusion of Ang-(1-7) improved renal endothelial function via Mas receptors, in an experimental model of human cardiovascular disease, by increasing levels of endogenous NO.